<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083809</url>
  </required_header>
  <id_info>
    <org_study_id>OxyDE</org_study_id>
    <nct_id>NCT02083809</nct_id>
  </id_info>
  <brief_title>Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation</brief_title>
  <official_title>A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is very little research to identify ways to decrease blood loss during D&amp;E
      (dilation and evacuation) procedures. The objective is to determine whether routine use of
      intravenous oxytocin will improve bleeding outcomes at the time of D&amp;E at 18-24-weeks
      gestation. To evaluate the hypothesis, investigators will perform a randomized,
      double-blinded, placebo-controlled trial. The patient will be followed until discharged from
      the postoperative care unit during which time patient satisfaction, pain score and
      postoperative bleeding will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate at which providers intervene to control blood loss during D&amp;E procedures.</measure>
    <time_frame>During surgical procedure</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Abortion</condition>
  <condition>Dilation and Evacuation</condition>
  <condition>Hemorrhage</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500ml saline or lactated ringer without oxytocin added</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous oxytocin mixed with saline or lactated ringer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous oxytocin</intervention_name>
    <description>30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Fluids and Electrolytes</intervention_name>
    <description>500 ml of inert IV fluid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requesting pregnancy termination

          -  Intrauterine pregnancy at 18- to 24-weeks gestation

          -  Gestational-age to be confirmed by ultrasound

          -  Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to
             24-weeks gestation

          -  Willing and able to understand and sign written informed consents in English or
             Spanish and comply with study procedures

        Exclusion Criteria:

          -  Ultrasound findings suggestive of placenta accreta

          -  Patients requiring preoperative misoprostol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bliss Kaneshiro, MD, MPH</last_name>
    <phone>808-203-6500</phone>
    <email>research@fpfellowshiphawaii.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Whitehouse, DO</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Whitehouse, DO</last_name>
    </contact>
    <contact_backup>
      <last_name>Bliss Kaneshiro, MD, MPH</last_name>
    </contact_backup>
    <investigator>
      <last_name>Bliss Kaneshiro, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kate Whitehouse, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Micks, MD, MPH</last_name>
    </contact>
    <investigator>
      <last_name>Elizabeth Micks, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 25, 2017</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hawaii</investigator_affiliation>
    <investigator_full_name>Bliss Kaneshiro</investigator_full_name>
    <investigator_title>Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
